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Identity 
Hugo: PLCB2 
Other names: FLJ38135 
Location: 15q15 
DNA/RNA 
Note: 32 exons; DNA size 19,93 kb. 
Transcription 
mRNA size 4518 bp. Two alternatively spliced forms 
of PLC-b2 have been identified: PLC-b2a and PLC-
b2b. 
The sequence of PLC-b2a consists of 1181 amino acids 
(molecular weight 133.7 kDa). PLC-b2b transcript 
lacks 45 nucleotides in the carboxyl-terminal region 
and the two splice variants differ by 15 amino acid 
residues, corresponding to aa 864-878. 
Pseudogene 
No known pseudogenes. 
Protein 
Description 
The sequence of PLC-b2 contains a PH-domain in the 
amino-terminal region, that binds to 
polyhosphoinositides and to cytoskeleton proteins. The 
catalytic site corresponds to the X and Y domains, 
highly conserved among PLCs. A C2 domain, present  
in numerous signaling molecules, is involved in the 
calcium binding. The long carboxyl-terminal region, 
located downstream to the C2 domain, is involved in 
the Gaq mediated activation of the catalytic domains 
and contains a nuclear localization signal. Additional 
EF domains are located between the PH and X regions 
and seem to simply constitute a flexible linker to the X-
Y domain. 
Expression 
PLC-b2, first isolated from a HL-60 cDNA library, is 
expressed predominantly in cells of haematopoietic 
origin. The amount of PLC-b2 correlates with the 
functional maturation of differentiating cells. In 
platelets, leukocytes and erythroleukemia cells, both 
the two alternatively spliced forms are present. 
PLC-b2 is weakly expressed in breast epithelial cells 
and shows high levels in tumoral mammary tissues. 
PLC-b2 was also identified in ATP-secreting taste bud 
cells. 
Localisation 
PLC-b2 has both a cytoplasmic and a nuclear 
localization. In particular, PLC-b2 accumulates inside 
the nuclear compartment during agonist-induced 
granulocytic differentiation of tumoral myeloid 
precursors. 
In platelets, expressing both splicing variants, PLC-b2a 
is most abundant in the nuclear compartment. By 
means of immunocytochemical analysis, it has been 
demonstrated that in promyelocytes differentiating  
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along the neutrophil lineage, PLC-b2 distribution 
evokes the spatial organization of the cytoskeleton. 
Function 
PLC-b2 catalyzes the hydrolysis of 
phosphatidylinositol 4,5-bisphosphate (PIP2) 
generating the second messenger molecules inositol 
1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). 
In hematopoietic cells, PLC-b2 plays a crucial role in 
platelet activation and in response of neutrophils to 
chemoattractants. 
During maturation of tumoral myeloid precursors, it 
has been demonstrated that the phosphodiesterase 
activity of PLC-b2 on the actin-associated PIP2 may be 
responsible, by modifying the phosphoinositide pools, 
for the modifications of cytoskeleton architecture that 
take place during motility of differentiating 
promyelocytes. 
In taste bud cells, PLC-b2 is a marker of early 
differentiation and functional taste signalling. 
Homology 
PLC-b2 is related to PLC-b1 with an amino acid 
sequence identity of 48%. 
Implicated in 
Acute Promyelocytic Leukaemia (APL) 
Note: This hematopoietic disorder is a M3 subtype of 
acute myeloblastic leukemia and is characterized by a 
block of granulocytopoiesis at the promyelocytic stage. 
APL blasts present a balanced reciprocal t(15;17) 
chromosomal translocation encoding the PML / RARA 
fusion protein that plays a key role in the pathogenesis 
of the disease. 
Disease 
PLC-b2, highly present in neutrophils of peripheral 
blood, is weakly expressed in blasts purified from 
patients with APL and in APL-derived cell lines. 
Prognosis 
PLC-b2 shows a large increase of expression during 
ATRA (all-trans-retinoic acid) and/or As2O3-induced 
granulocytic differentiation of both APL-derived cell 
lines and blasts purified from patients with APL. PLC-
b2 expression during differentiating treatments 
correlates with the granulocytic maturation levels 
reached by myeloid precursors. In addition, the level of 
PLC-b2 after ex-vivo ATRA treatment of APL blasts 
strikingly correlates with the responsiveness of APL 
patients to ATRA-based therapies. 
This evidence demonstrates that PLC-b2 represents a 
specific marker for monitoring the agonist-induced 
overcoming of the maturation blockade of tumoral 
promyelocytes. 
Oncogenesis 
It has been reported that co-repressors bound to PML-
RARa are released from DNA upon both ATRA and 
As2O3-treatment of APL cells leading to the activation 
of genes repressed by the fusion protein. This suggests 
that the reduced expression of PLC-b2, whose gene is 
located on chromosome 15, which is involved in the 
(15;17) translocation, may be related to the presence of 
the fusion protein. The increased expression of PLC-
b2, induced by both ATRA and As2O3, may be related 
indeed to the removal of the fusion protein, that seems 
to constitute a common step of the differentiation 
pathways activated by the two agonists. 
Breast cancer 
Note: Breast cancer is highly heterogeneous and, 
during its sequential in vivo progression from atypical 
hyperproliferation to metastatic disease, tumor cells 
undergo phenotype alterations, including the loss, to a 
variable extent, of epithelial-like features, and the gain 
of more aggressive and invasive mesenchymal-like 
traits. Like most human neoplasm, breast cancer has 
aberrations in signal transduction elements that can 
lead to increased proliferative potential, sustained 
angiogenesis, apoptosis inhibition and tissue invasion 
and metastasis. The portrait of breast tumors remains 
stable during progression and no major changes appear 
to explain why a tumor may evolve to the metastatic 
stage and, at present, no marker has been clearly 
associated with the progression from in situ to 
invasiveness. 
Disease 
It has recently been demonstrated, by means of 
immunohistochemical analysis on tissue microarrays 
composed of breast cancer specimens and normal 
epithelia, that PLC-b2, poorly expressed in normal 
tissues, is up-regulated in almost all tumor cells. In 
particular, the amount of PLC-b2 correlates with 
morphological features of the different primary 
cancers, since weak expression is showed by tumors 
that retain a differentiated appearance, while a 
progressively higher amount of protein was revealed in 
poorly differentiated and undifferentiated tumors. 
Prognosis 
By analyzing the relationship between PLC-b2 levels 
and biological and clinic-pathological factors, it has 
been found that the expression of PLC-b2 strikingly 
correlates with histological grade, mitotic index and 
size of primary tumors. No differences in PLC-b2 
amount were found in breast tumors that express 
estrogens and/or progesterone receptors, while tumors 
negative for at least one of the two receptors showed 
elevated expression of this enzyme, as well as the 
majority of HER-2 positive tumours. These data 
suggest that high amounts of PLC-b2 might be 
associated to a worse response to therapy. 
Survival analysis of cancer-related death indicates that 
patients whose primary tumors express low levels of 
PLC-b2 show an overall survival significantly higher in 
comparison to patients whose primary tumors express 
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high levels of protein. In addition, elevated PLC-b2 
expression of primary breast cancer is associated with a 
shorter relapse-free time interval. 
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